Антифосфолипидный синдром - часть 105

425

on aspirin. ACR 66th Annual Scientific Meeting,
New Orleans, 2002;1663 (abst).

47. Ko D, Wang Y, Berger AK, et al. Nonste

roidal antiinflammatory drugs after acute
myocardial infarction. Am Heart J 2002; 143:
475—481.

48. Garcia Rodriguez LA. The effect of NSAIDs

on the risk of coronary heart disease: fusion of
clinical pharmacology and pharmacoepidemilog
ic data. Clin Exp. Rheumatol. 2001; 19 (suppl.
25): S41—S45.

49. Ray WA, Stein CM, Hall K, et al. Non

steroidal antiinflammatory drugs and risk of
serious coronary heart disease: an observational
cohort study. Lancet 2002; 359: 118—123.

50. Bak S, Andersen M, Tsiropoulos I, et al.

Risk of stroke associated with nonstweroidal
antiinflammatory drugs, Stroke 2003;3 4:
379—395.

51. Layton D, Hughes K, Harris S, Shakir

SAW. Comparison of the incidence rates of
thromboembolic events reported for patients pre
scribed celecoxib and meloxicam in general prac
tice in England using PrescribtionEvents Moni
toring (PEM) data. Rheumatology 2003; 42: 1—
11.

52. Vane JB. Back to an aspirin a day. Science

2002; 296: 474—475.

53. СatellaLawson F, Reilly MP, Kapoor SC,

et al. Cyclooxygenase inhibitors and the
antiplatelet effect of aspirin. N Engl J Med 2001;
345: 1809—1817.

54. Van Solingen RM, Rosenstein ED, Mihai

lescu G, et al. Comparison of the effects of ketopro
fen on platelet function in the presence and absence
of aspirin Am. J Med 2001; 111: 285—289.

55. Ouellett M, Riendeau D, Percival D. A high

level of cyclooxygenase2 inhibitor selectivity is
associated with a reduced intereference of platelet
cyclooxygenase1 inactivation by aspirin. PNAS
2001; 98: 14583—14588.

56. Greenberg H, Gottesdiener K, Huntington

M, et al. A new cyclooxygenase2 inhibitor, rofe
coxib (VIOXX), did not alter the antiplatelet
effects of lowdose aspirin in healthy volunteers. J
Clin Pharm 2000; 40: 1509—1515.

57. MacDonald TN, Wei L. Effect of ibuprofen

on cardioprotective effect of aspirin. Lancet 2003;
361: 573—574.

58. Kurth T, Glynn RJ, Walker AM, et al. Inhi

bition of clinical benefits of aspirin on first
myocardial infarction by nonsteroidal anti
inflammatory drugs. Circulation 2003; 108:
1191—1195.

59. Derry S, Loke YK. Risk of gastrointestinal

haemorrage with long term use of aspirin. BMJ
2000; 321: 1183—1187.

60. Pickard AS, Scumock GT. Aspirin use may

change costeffectiveness of COX2 inhibitors.
Arch Intern Med 2002; 162: 2637—2639.

61. Fendrick AN, GarabedianRufallo SM. A

clinician,s guide to the selection of NSAID thera
py. Pharm Ther 2002; 27: 579—582.

62. Silverstein FE, Faich G, Goldstein JL, et al.

Gastrointestinal toxicity with celecoxib versus
nonsteroidal antiinflammatory drugs for osteo
arthritis and rheumatoid arthritis: the CLASS
study: a randomized controlled trial. Celecoxid
longterm arthritis saferty. JAMA 2000; 284:
1247—1255.

63. Deeks JJ, Smith LA, Bradley MD. Efficacy,

tolerability, and upper gastrointestinal safety of
celecoxib for treatment of osteoarthiritis and
rheumatoid arthritis: systemic review of random
ized controlled  trials. BMJ 2002; 325: 1—8.

64. Baker CS, Hall RJ, Evans TJ et al.

Cyclooxygenase 2 is widely expressed in  athero
sclerotic lesions affecting native and transplanted
human coronary arteries and colocalized with
inducible nitric oxide synthase and nitrotyrosine
particularly macrophages. Atheroscler Thromb
Vasc Biol 1999; 19: 646—655.

65. Schonbeck U, Sukhova GK, Graber P, et al.

Augmented expression of cyclooxigenase2 in
human atherosclerotic lesions. Am J Pathol 1999;
155: 1281—1291.

66. Burleigh ME, Babaev VR, Oates JA, et al.

Cyclooxygenase2 promotes early atherosclerotic
lesion formation in LDL receptor deficiency mice.
Circulation 2002; 105: 1816—1823.

67. Cippilone F, Prontera C, Pini B, et al.

Overexpression of functionally coupled cyclooxy
genase E synthase in symptomatic atherosclerot
ic plaques as a basis of prostaglandin E2depen
dent plaque instability. Circulation 2001; 104:
921—930.

68. Belton O, Byrne D, Kearney D, et al. Cyclo

oxygenase1 and — 2 dependent prostacyclin for

ГЛАВА 14. Новые подходы к профилактике и лечению антифосфолипидного синдрома

Насонов Е.Л. Антифосфолипидный синдром

426

mation in patients with atherosclerosis. Circulation
2000; 102: 840—845.

69. Saito T, Rodger IW, Hu E, et al. Inhibition

of cyclooxygenase2 improves cardiac function in
myocardial infarction. Biochem Biophys Res
Commun 2000; 273: 772—775. 

70. Chenevard R, Hurlimann D, Bechir M, et

al. Selective COX2 inhibition improves endothe
lial function in coronary artery disease.
Circulation 2003; 107.

71. Heindt H, Becker BF. Aspirin, but not the

more selective cyclooxygenase (COX)2 inhibitors
meloxicam and SC 58125, aggravates posis
chemic cardiac dysfunction, independent of COX
function. NaunynSchmiedeberg`s Arch Pharma
col.,2001; 363: 233—240.

72. Altman R, Luciardi HL, Muntaner J, et al.

Efficacy of assessment of meloxicam. A preferen
tial COX2 inhibitor in acute coronary syndromes
without STsegment elevation, the NUT2 pilot
study. Circulation 2002; 106: 191—195.

73. Howard PA. Aspirin resistance Ann

Pharmacotherapy 2002; 36: 1620—1624.

74. Gum PA, KottkeMarchant K, Poggio Ed, et

al. Profile and prevalence of aspirin resistence in
patients with cardiovascular disease.  Am J
Cardiol 2001; 88: 230—234.

75. Weber AA, Zimmermann KC, Meyer

Kirchrath J, Schor K. Cyclooxygenase2 in
human platelets as a possible factor in aspirin
resistence. Lancet 1999; 353: 900.

76. Rocca B, Secchiero P, Giabattoni G, et al.

Cycloxygenase2 expression is induced during
human megakaryopoiesis and characterizes newly
formed platelets. PNAS 2002; 99: 7634—7639.

77. Halushka MK, Halushka PV. Why are

some individuals resistant to the cardioproyective
effects of aspirin. Could it be thromboxane A

2

.

Circulation 2002; 105: 1620—1622.

78. Eikelboom JW, Hirch J, WeitJi, et al.

Aspirinresistant thromboxane biosynthesis and
risk of myocardial infarction, stroke. Or cardio
vascular death in patients at high risk for cardio
vascular events. Circulation 2002; 105: 1650—
1655.

79. Ferro D, Basill S, Roccaforte S, et al. Deter

minants of enhanced thromboxane biosynthesis in
patients with systemic lupus erythematosus.
Arthritis Rheum 1999; 42: 2689—2697.

80. Azar RR, Rinfret S, Theroux P, et al. A ran

domized placebocontrolled trial to asses the effi
cacy of antiinflammatory therapy with methyl
prednisolone in unstable angina. (MUNA trial).
Eur Heart J 2000; 21: 2026—2032.

81. Versaci F, Gaspardone A, Tomai F, et al.

Immunosupressive therapy for the prevention of
restenosis after coronary artery stent implantation
(IMPRESS Study). J Am Coll Cardiol 2002; 40:
1935—1942.

82. Cippolone F, Ganci A, Greco A, et al. Modu

lation of aspirininsensitive eicosanoid biosynthe
sis by 6methylprednisolone in unstable angina.
Circulation 2003; 10&: 55.

83. Weyand CM, Kaiser M, Yang H, et al.

Therapeutic effects of acetylsalicylic acid in giant
cell arteritis. Arthritis Rheum 2002; 46: 457—466.

84. Nesher G, Mates M, Barkum Y, et al. Low

dose aspirin and prevention of stroke and visual
loss in giant cell arteritis. ACR 6 Annual
Scientific Meeting, Oktober 24—29, 2002; 402
(abst).

Противовоспалительные эффекты ингиби

торов АПФ и антагонистов рецепторов ан
гиотензина II типа I 

1. Linz W, Wohlfart P, Schoelkens Ba, et al.

Interactions among ACE, kinins and NO.
Cardiovasc Res 1999; 43: 549—561.

2. Schieffer B, Schieffer E, HilfikerKleiner D,

et al. Expression of angiotensin II and interleukin
6 in human coonary atherosclerotic plaques:
potential implications for inflammation and
plaque stability. Circulation 2000; 101: 1372—
1378.

3. Kranzhofer R, Scmidt J, Pfeifer CAH, et al.

Angiotensin induced inflammatory activation of
human vascular smooth muscle cells. Arteriol
Thromb Vasc Biol 1999; 19: 1623—1629.

4. Bunte C, Witte J, Hoeper K, Schieffer B.

Contrasting antiatherosclerotic effects of AT1
antagonism and ACE inhibition in patients with
coronary artery disease: potential impact on
plaque passivation. Circulation 2002; 19: II—
337. (abst 1684).

5. Napoleone E, Di Santo A, Camera M, et al.

Angiotensinconverting enzyme inhibitors down
regulate tissue factor synthesis in monoyte. Circ
Res 2000; 86: 139—143.

427

6. Soejima H, Ogawa H, Yasue H, et al.

Angiotensinconverting enzyme inhibition
reduces monocyte chemoattractant protein1
and tissue factor levels in patients with myocar
dial infarction. J Am Col Cardiol 1999; 34:
983—988.

7. Sadoshima J. Novel AT1 receptor — inde

pendent functions of losartan. Circ Res 2002; 90:
754—756.

8. Kramer S, Sunkomat J. Witte J, et al. An

giotensin II receptor — independent antiinflam
matory and antiaggregatory oroperties of losar
tan: role of active metabolite EXP3179. Circ Res
2002; 90: 770—776.

9. Schwemmer M, Sommer O, Bassenge E. Blo

cade of angiotensin signaling improves myocatdi
al function in hypercholesterolemia independent
of changes in ecosanoid release. Cardiovasc Drug
Ther 2000; 14L 317—327.

10. Maeso R, Rodrigo E, MunozGarcia R, et

al. Lasartan reduces constrictor responses to
endothelin1 and thromboxane A

2

analogue in

aortic rings from spontaneously hypertensive rats:
role of nitric oxide. J Hypertension 1997; 15:
1677—1684.

11. Bertolino F, Valentin JP, Maffre M, et al.

Prevention of thromboxane A

2

receptormediated

pulmonary hypertension by a nonpeptide angio
tensin II type receptor antagonist. J Pharmacol
Exp Ther 1994; 268: 747—752.

12. Li P, Ferrario CM, Brosnihan KB. Nonpe

ptide angiotensin II antagonist losartan inhibits
thromboxane A

2

induced constrictions in canine

coronary artery. J Pharmacol Exp. Ther 1997;
281: 1065—1070.

13. Valentin JP, Jover B, Maffe M, et al.

Lozartan prevents thromboxane A2/prostanoid
(TP) receptot mediated increase in microvascular
permeability in the rat. Am J Hypertension 1997;
10: 1058—1063.

14. Picard P, Chretien L, Couture R. Func

tional interaction between losartan and central
tachykinin NK3 receptors in the conscious rat. Br
J Pharmacol 1995; 114: 1563—1570.

15. Li Z, Bosch SM, Smith TL, Diz DI. Inte

ractions of nonpeptide angiotensin II receptor
antagonists at imidazoline/guanidinium receptor
sites in rat forebrain. J Cardiovasc Pharmacol
1996; 28: 425—431.

Аминохинолиновые препараты (гидроксих

лорохин)

1. Насонов ЕЛ, Иванова ММ. Антималя

рийные (аминохинолиновые) препараты: но
вые фармакологические свойства и перспек
тивы клинического применения Клин. фарма
кол. терапия, 1998; 3: 65—68.

2. Wallace DJ. The use of chloroquine and

hydroxychloroquine for noninfections conditions
other than rheumatoid arthritis or lupus: a critical
review. Lupus 1996; 5 (Suppl 1): S59—S64.

3. Janicinova V, Nassal R, Petrikova M. On the

inhibitory effect of chloroquine on blood platelet
aggregation. Thromb Res 1995; 77: 531—542.

4. Wallace DJ. Does hydroxychloroquine sulfate

prevent clot formation in systemic lupus erythe
matosus? Arthritis Rheum 1987; 30: 1435—1456.

5. Wallace DJ, LinkerIsraeli M, Metzger AL,

Stecher VJ. The revalence of antimalarial thera
py with regard thrombosis, hypercholesterolemia
and cytokines in SLE. Lupus 1993; 2 (Suppl 1):
S13—S15.

6. Petri M, Hochberg M, Hellmann D, et al.

Incidence and predictors of thrombotic events in
SLE: protective role of hydroxychloroquine.
Arthritis Rheum 1992; 35 (Suppl 9):S54.

7. McCarty. Hydroxychloroquine treatment in

antiphospholipid antibody syndrome: time course
of clinical improvement and antiphpspholipid
antibody titer changes over 4 years. Arthritis
Rheum 2000; 43 (Suppl): 9: S1061. 

8. Edwards MH, Pierangeli S, Liu XW, et al.

Hydroxychloroquine reserves thrombogenic prop
erties of antiphospholipid antibodies in mice.
Circulation 1997; 96: 4380—4384.

9. Cho CS, Cho ML, Min SY, et al. Hydroxy

chloroquine inhibits the production of monocyte
chemoattractant protein 1 in endothelial cell.
Implication of its therapeutic use in antiphospholipid
syndrome. ACR/ARHP Annual Scientific Meeting,
Orlando, October 24—28, 2003; 321 (abst). 

10. Espinola RG, Pierangeli SS, Ghara AE,

Harris EN. Hydroxychloroquine reverses platelet
activation induced by human IgG antiphospho
lipid antibodies. Thromb Haemost 2002; 87:
518—522.

11. Beynen AC. Can chloroquine be of value in

the treatment of hypercholesterolemia? Artery
1986; 13: 340—351.

ГЛАВА 14. Новые подходы к профилактике и лечению антифосфолипидного синдрома

Насонов Е.Л. Антифосфолипидный синдром

428

12. Svenson KLG, Lithell H, Hillgren R, Vessby

B. Serum lipoprotein in active rheumatoid arthri
tis and other chronic inflammatory arthritides.II
Effects of antiinflammatory and diseasemodify
ing drug treatment. Arch Intern Med 1987; 147:
1917—1920.

13. Petri M. Hydroxychloroquine use in the

Baltimore Lupus Cohort: effects on lipid, glucose
and thrombosis. Lupus 1996; 5 Suppl 1: 16—22.

14. Wallace DJ, Metzger AL, Stecher VJ, et al.

Cholesterollowering effect of hydroxychloroquine
in patients with rheumatic disease: reversal of
deletetious effects of steroid on lipid. Am J Med
1990; 89: 322—326.

15. Borba EF, Bonf E. Longterm beneficial ef

fect of chloroquine diphosphonate on lipoprotein
profile in lupus patients with and without steroid
therapy. J Rheumatology 2001; 28: 780—785.

16. Powrie JK, ShojaeeMaradie F, Watts GF,

et al. Effects of chloroquine on the dyslipidemia of
noninsulinedependent diabetes mellitus.
Metabolism 1993; 42: 415—419.

17. Petri M, Lakata C, Madger L, Goldman D.

Effect of prednisolon and hyroxychloroquine on
coronary artery risk factors in systemic lupus ery
thematosus: a longitudinal data analysis. Am J
Med 1994; 96: 254—259.

18. Wallace DJ, Metzger AL, Stecher VJ, et al.

Cholesterollowering effect of hydroxychloroquine
in patients with rheumatic disease: reversal of
deleterious effects of steroids on lipids. Am J Med
1990; 89: 322—326.

19. Hodis NH, Quismorio FP, Wickham E. et

al. The lipid, lipoprotein, and apolipoprotein
effects of hydroxychloroquine in patients with sys
temic lupus erythematosus. J Rheumatol 1993;
20: 661—665.

20. Kavanaugh A, AdamsHuet B, Jain R, et al.

Hydroxychloroquine effect on lipoprotein profiles
(HELP trial): a doubleblind, randomized placebo
controlled pilot study in patients with systemic lupus
erythematosus. J Clin Rheumatol 1997; 3: 3—8.

21. Rahman P, Gladman DD, Urowitz MB, et

al. The cholesterol lowering effect od antimalarial
drugs is enhanced in patients with lupus taking
cortocosteroid drugs. J Rheumatol 199; 26: 325—
330.

22. Tam LS, Li EK, Lam CW, Tomlison B.

Hydroxychloroquine has no significant effect on

lipids and apolipoproteins in Chinese systemic
lupus erythematosus patients with mild or inactive
disease. Lupus 2000; 9: 413—416.

23. Tam LS, Gladman DD, Hallett D, et al.

Effect of antimalarial agents on the fasting lipid
profile in systemic lupus erythematosus. J
Rheumatology 2000; 27: 2142—2145.

24. Munro R, Morrison E, McDonald AG, et al.

Effect of disease modifying agents on the lipid pro
files of patients with rheumatoid arthritis. Ann
Rheum Dis 1997; 56: 374—377.

Cтатины 
1. Knopp RH. Drug treatment of lipid disorders.

New Engl J Med 1999; 498—511.

2. Vaughan CJ, Gotto AM, Basson CT. The evo

lving role of statins in the management of athroscle
rosis, J Amer Col Cardiol 2000; 35: 1—10.

3. Шевченко ОП, Шевченко АО. Статины.

Ингибиторы ГМГКоА редуктазы. Москва:
Реафарм, 2002; 112 с.

4. Chong PH, Seeger JD, Franklin C. Clinically

relevant differences the statins: implication for ther
apeutic selection. Am J Med 2001; 111: 390—400.

5. La Roa JC, He J, Vupputuri S. Effect of

statins on risk of coronary disease. A Metaanaly
sis of randomized controlled trials. JAMA 1999;
282: 2340—2346.

6. HMGCoa reductase inhibitors. Ed. Schmitz

G, Torzewski M. Birkhauser Verlag. Basel,
Boston, Berkin 2002; 151 p.

7. Salan AM. Expanding indications of statins:

implications of the Heart Protecion Study. Exp.
Opin Invest Drugs 2003; 12: 509—513.

8. Goldstein JL, Brown MS. Regulation of the

mevalonate pathway. Nature 1990; 343: 425—430.

9. Takemoto M, Liao JK. Pleotropic effects of 3

hydroxy3methylglutaril coenzyme A reductase
inhibitors. Arteriol Thromb Vasc Biol 2001; 21:
1712—1719.

10. Farmer JA. Pleitropic effevts of statins.Curr

Atherosclerosis report 2000; 2: 208—217.

11. Munford RS. Statins and the acutephase

response. New Engl J Med 2001; 344: 2016—
2018.

12. Shovman O, Gilburd B, Shoenfeld Y. Anti

inflammatory and immunomodulatory properties
of statins. www.rheuma21. com/archives/cut
ting_report_shoenfeld_antiinfl_statins.html.